NMPA approved phase Ib/II clinical trial application of ImmuneOnco for IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors

On February 22, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that National Medical Products Administration (NMPA) approved Phase Ib/II clinical trial application of the first domestic SIRPα-F......

2022-02-22

IMM2902 of ImmuneOnco Completed the First Patient Dosing

February 15, 2022, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting hum......

2022-02-15

ImmuneOnco grandly held the groundbreaking ceremony of its headquarter and biopharmaceutical manufacturing base

The first sod was turned in the morning on the first working day of the new year (January 4, 2022). The groundbreaking ceremony of "ImmuneOnco Headquarter and Biopharmaceutical Manufacturing Base" was grandly held in the campus of ‘Innovative Medicine Bas......

2022-01-04

ImmuneOnco is enlisted in‘’2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China‘’

Dec. 21, 2021, Shanghai, China. The list of ‘2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China’ was made public today. ImmuneOnco was successfully selected for the name of the list and it is highly recognize......

2021-12-21

ADCC-enhanced CTLA-4 Antibody of ImmuneOnco Received Approval of NMPA for Clinical Trial

On November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADCC-enhanced CTLA-4 antibody was approved by NMPA for clinical trial research. This is another major milestone for ImmueOnco. ......

2021-11-05